• Faculty of Clinical Research (FCR)
  • Global accredited training & certification provider cleanindia
  • Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India.
  • ApprovedTraining Partner of Food Safety and Standards Authority of India (FSSAI)
  • An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India
  • Empanelled under Ministry of Horticulture and Food Processing, Govt. of Uttar Pradesh
  • Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC) set up by National Skill Development Corporation (NSDC)
  • Conferred with QUALITY COUNCIL OF INDIA (QCI) – D.L. SHAH NATIONAL QUALITY AWARD & ASSOCHAM Services Excellence Award 2017
  • Trusted by organizations & training participants in over 30 countries
    Training | Certification | Education | Research

Honourable Dr. G. N. Singh, Drug Controller General of India presented a Momento by our Director Mr. Syed S. Abbas & Principal Advisor Mr. Vinod Arora on the launch of our Computer System Validation (CSV) programme

IGMPI is conferred with ASSOCHAM Services Excellence Award 2017: Our Directors Mr Syed S. Abbas & Mrs Rafat Abedi, Chief Advisor Dr Mahesh Gupta, Advisor Mr Amitabh Srivastava are being honoured by the Chief Guest & Honorable Member of Parliament Dr. Udit Raj


A new drug for treating Alzheimer’s disease developed by a Chinese research group completes phase 3 clinical trial

A new drug for treating Alzheimer’s disease developed by a Chinese research group completes phase 3 clinical trial

Alzheimer’s is an irreversible progressive brain disorder which has no effective cure and affects almost 48 million people worldwide. In this disease memory thinking skills are slowly destroyed due to which the patient loses ability to carry out simple tasks. The number of affected people is expected to increase with aging population.

A drug named GV-971 which has been developed by Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences and Green Valley Pharmaceutical Co. Ltd, has completed phase 3 clinical trial which is the last test before a drug is launched in the market. The drug has opened a new gate for treatment with giving the hope of new solution to the affected patients.

The drug has been extracted from brown algae and is targeted at patients with mild to moderate Alzheimer’s disease. In the phase 3 trial, participants were given a dose of 450 mg of GV-971 orally twice a day for 36 weeks. The results showed improved cognition among the participants. Preclinical trials with the drug already showed that the drug can regulate the immune system, reduce neuroinflammation and can improve cognition.